Ras proteins regulate cell growth, differentiation and apoptosis. Their activities depend on their anchorage to the inner surface of the plasma membrane, which is promoted by their common carboxy-terminal S-farnesylcysteine and either a stretch of lysine residues (K-Ras 4B) or S-palmitoyl moieties (H-Ras, N-Ras and K-Ras 4A). We previously demonstrated dislodgment of H-Ras from EJ cell membranes by S-trans,trans-farnesylthiosalicylic acid (FTS), and proposed that FTS disrupts the interactions between the S-prenyl moiety of Ras and the membrane anchorage domains. In support of this hypothesis, we now show that FTS, which is not a farnesyltransferase inhibitor, inhibits growth of NIH3T3 cells transformed by the non-palmitoylated K-Ras 4B(12V) or by its farnesylated, but unmethylated, K-Ras 4B(12) CVYM mutant. The growth-inhibitory effects of FTS followed the dislodgment and accelerated degradation of K-Ras 4B(12V), leading in turn to a decrease in its amount in the cells and inhibition of MAPK activity. FTS did not affect the rate of degradation of the K-Ras 4B, SVIM mutant which is not modified post-translationally, suggesting that only farnesylated Ras isoforms are substrates for facilitated degradation. The putative Ras-recognition sites (within domains in the cell membrane) appear to tolerate both C 15 and C 20 S-prenyl moeities, since geranylgeranyl thiosalicylic acid mimicked the growth-inhibitory effects of FTS in K-Ras 4B(12V)-transformed cells and FTS inhibited the growth of cells transformed by the geranylgeranylated K-Ras 4B(12V) CVIL isoform. The results suggest that FTS acts as a domain-targeted compound that disrupts Ras^membrane interactions. The fact that FTS can target K-Ras 4B(12V), which is insensitive to inhibition by farnesyltransfarase inhibitors, suggests that FTS may target Ras (and other prenylated proteins important for transformed cell growth) in an efficient manner that speaks well for its potential as an anticancer therapeutic agent. ß 1999 Elsevier Science B.V. All rights reserved.
Introduction
The small G-proteins K-Ras (the 4A and 4B isoforms), H-Ras and N-Ras are essential components of signaling pathways that regulate cell growth, differentiation and apoptosis [1^6] . These four proteins share a high degree of amino acid identity (90%) and have similar biochemical and biological activities [7, 8] . They operate as signal regulators of a large number of cell-surface receptors where receptor signaling through Ras involves activation of Ras exchange of GDP for GTP, interactions of Ras-GTP with Ras-e¡ector molecules, and inactivation of Ras by GTPase-activating proteins that facilitate GTP hydrolysis by Ras [1, 4, 9] . Mutations in Ras genes, mostly point mutations at codons 12, 13 and 61, are common in many types of human cancers [7, 8] . These mutations result in constitutively active ras gene products which are permanently bound to GTP and contribute to uncontrolled cell growth and transformation [7, 8] .
Ras-dependent signaling and transforming activities require not only that Ras be bound to GTP, but also that it be associated with the inner lea£et of the plasma membrane [3,10^15] . Membrane anchorage of Ras proteins is promoted by their C-terminal S-farnesylcysteine and by either a stretch of lysine residues (K-Ras 4B isoform) or S-palmitoyl moieties (H-Ras, N-Ras and K-Ras 4A isoforms) [3,10^16] . The anchoring moieties of Ras proteins also appear to target these proteins to the plasma membrane [3,10^16] , possibly to speci¢c membrane microdomains [17^20] .
On the assumption that Ras functions can be inhibited by dislodgment of the mature protein from its putative membrane-anchorage domains, we recently designed a series of organic compounds resembling the farnesylcysteine of Ras proteins [21, 22] . Among these compounds, S-trans,trans-farnesylthiosalicylic acid (FTS) was found to be a potent growth inhibitor of H-Ras-transformed Rat-1 (EJ) ¢broblasts, a¡ect-ing speci¢cally the membrane-bound H-Ras protein in these cells [21,23^25] . FTS a¡ected H-Ras-membrane interactions both in vivo and in vitro, dislodging the protein from its anchorage domains and facilitating its degradation [24] . These e¡ects appeared to be speci¢c to the farnesylated Ras protein, as FTS did not dislodge the prenylated GLQ subunits of heterotrimeric G-proteins from Rat-1 cell membranes and had no e¡ect on the genetically engineered Nmyristoylated (unfarnesylated) H-Ras protein myrRas in myr-Ras-transformed cells [24] . Growth of the myr-Ras-transformed cells was not inhibited by FTS [24] . Our earlier demonstration that FTS can inhibit the growth of ¢broblasts transformed by ErbB2 acting upstream of Ras, but not the growth of cells transformed by v-Raf or by SV40 T-antigen acting independently of Ras, suggested speci¢city of FTS towards Ras and Ras driven cell growth [23] . Clearly then, FTS does not present a global growth inhibitory e¡ect on normal cells or on every type of transformed cell [23^25] . These results, as well as the observed dislodgment of wild-type Ras isoforms in untransformed Rat-1 cells, also suggested that FTS might a¡ect all types of Ras proteins, not only the activated H-Ras [24] . Moreover, because FTS is structurally similar to the S-farnesyl cysteine common to all Ras proteins, we proposed that it may interfere with anchorage domains that recognize the S-prenyl moiety of Ras [24, 25] . Because these possibilities were not put to the test, we undertook to examine the e¡ects of FTS and its analogs on K-Ras 4B a non-palmitoylated Ras isoform in the present study. Also, because H-ras mutations are relatively rare in human cancers compared to mutations in K-and N-ras genes [7, 8] , we considered it important to examine whether FTS can a¡ect these Ras proteins and their growth-promoting and transforming activities. The potential importance of such studies is also highlighted by the results of recent experiments demonstrating that K-and N-Ras proteins can also be prenylated by the enzyme geranylgeranyltransferase I [26^29]. Since geranylgeranylated activated Ras proteins exhibit biological activity [13, 15, 30] , farnesyltransferase inhibitors may not directly block K-or N-Ras functions [3] .
In the present study, we demonstrate that FTS a¡ects various isoforms of activated K-Ras 4B in NIH3T3 cells. We show that these e¡ects are manifested in dislodgment of the constitutively active K-Ras 4B(12V) from the cell membrane and its accelerated degradation, inhibition of Ras-dependent signaling to the mitogen-activated protein kinase (MAPK) ERK, and inhibition of cell growth. This result clearly distinguishes the action of FTS from that of FTIs, which are currently in clinical trials for cancer treatment. Treatment of H-Ras with FTIs easily results in a completely unprocessed, inactive protein, whereas treatment of K-Ras 4B with FTIs either fails to inhibit processing altogether or results in an alternatively prenylated form of protein that remains active. Since K-Ras 4B is the most commonly mutated form of ras in human tumors, the ability of FTS to target both H-and K-Ras is a very important ¢nding.
Materials and methods

Materials
[Q-
32 P]ATP (3000 Ci/mmol) was purchased from Rotem Industries, Negev, Israel. 35 S-Cysteine/methionine (express 35 S-protein labeling) (1000 Ci/mmol) was purchased from DuPont, New England Nuclear. Anti-Ras antibodies (Pan-Ras antibody-3 (Pan-Ras Ab) and Y13-259 Ab) were purchased from Oncogene Research Products. Anti-ERK2 antibodies were purchased from Santa-Cruz. Goat anti-mouse IgG horseradish peroxidase, myelin basic protein (MBP), protein A Sepharose and protein G sepharose were all from Sigma. Dulbecco's modi¢ed Eagle's medium (DMEM) (high glucose), L-glutamine, penicillin-streptomycin, trypsin/EDTA and fetal calf serum (FCS) were from Biological Industries, Beit HaEmek, Israel. Calf serum (CS) and G418 were purchased from Gibco.
FTS, 5-£uoro-FTS (5-Fl-FTS), geranylthiosalicylic acid (GTS) and geranylgeranyl thiosalicylic acid (GGTS) were prepared by a general procedure and puri¢ed and analyzed as described in detail elsewhere [21, 22] .
Methods
Cell culture procedures
EJ cells, Rat-1 cells and myr-v-h-Ras(12V)-transformed Rat-1 cells have been described previously [23, 24] . These cell lines were grown in DMEM, 10% FCS and 400 Wg/ml G418 at 37³C in a humidi¢ed atmosphere of 95% air/5% CO 2 .
NIH3T3 cells stably expressing K-Ras 4B(12V), K-Ras 4B(12V) 187Y (K-Ras 4B(12V) CVYM), K-Ras 4B(12V) 185S (K-Ras 4B(12V) SVIM) and K-Ras 4B(12V) 188L (K-Ras 4B(12V) CVIL) have been described previously [14, 15, 31, 32] . These cell lines were grown in DMEM, 10% CS and 400 Wg/ ml G418 at 37³C in a humidi¢ed atmosphere of 95% air/5% CO 2 .
To estimate the e¡ects of FTS and its analogs on cell growth, cells were plated at a density of 2500 cells per well in 24-well plates, to which either 0.1% DMSO (carrier solution, control) or the indicated concentration of the analog was added after 3 h. Treated cells were grown for 5 days, detached from the plates and counted.
Determination of Ras
Ras was assayed by enhanced chemiluminescence (ECL) assays following immunoblotting [24] . K-Rastransformed NIH3T3 cells were plated at a density of 4U10 6 cells/10-cm dish. After 24 h, the cells were treated for 15 h (dose^response experiments) or for 2, 4 or 24 h (time-course experiments) with FTS (05 0 WM for dose response, 25 WM for time course) or with 0.1% DMSO (control). The cells were then detached from the dishes and washed in phosphatebu¡ered saline (PBS). All subsequent procedures were carried out at 4³C. Cell pellets were homogenized in 750 Wl of homogenization bu¡er (20 mM TrisHCl pH 7.6, 5 Wg/ml leupeptin, 5 Wg/ml pepstatin, 1 mM benzamidine, 1 mM phenylmethylsulfonyl £u-oride, 5 units/ml aprotinin and 10 mM MgCl 2 ) and the total amount of protein was determined. FTS had no e¡ect on the total amount of protein per cell. Total cell membrane (P 100 ) and total cytosol (S 100 ) fractions were obtained by centrifugation at 100 000Ug (30 min) . Following resuspension of the P 100 fraction in 750 Wl of homogenization bu¡er, S 100 , P 100 and the total homogenate were placed in 75 Wl of U10 solubilization bu¡er (100 mM Tris-HCl pH 7.5, 1.5 M NaCl, 10% Triton X-100, 5% Nadeoxycholate). Samples were frozen for 1 h at 370³C and then thawed. Insoluble material was removed by centrifugation for 10 min at 10 000Ug and the clear supernatants were used. Samples of the total cell homogenate (15 Wg protein) or of P 100 and S 100 fractions (10 to 30 Wg protein) were separated by 12.5% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) (mini-gel) and blotted onto nitrocellulose paper. The paper was blocked with 1.5% skim milk in Tris-bu¡ered saline pH 7.6 (containing 0.05% Tween-20 and 150 mM NaCl) overnight, then incubated for 1.5 h with 1:2000 dilution of Pan-Ras Ab in the same bu¡er. Immunoblots were then incubated for 1 h with 1:7500 dilution of anti-mouse IgG horseradish peroxidase conjugate and subjected to enhanced chemiluminescence (ECL) assays. Bands were quanti¢ed by densitometry on a BioImaging System 202D System (Dynco-Renium, Jerusalem) using Tina 2.0 software (Ray Tests).
Release of Ras from the membranes in a cell-free system was assayed as described previously [24] . Brie£y, 15 Wg of membrane protein (P 100 fraction) were incubated for 60 min at 37³C in 100 Wl of bu¡er A (10 mM Tris-HCl, pH 8.5, 0.32 M sucrose, 1 mM EDTA, 5 Wg/ml pepstatin, 5 units/ml aprotinin, 5 Wg/ ml leupeptin, 1 mM phenylmethylsulfonyl £uoride, 1 mM benzamidine and 1 mM MgCl 2 ) containing 2% DMSO and 25 WM FTS or in 100 Wl of bu¡er A containing 2% DMSO only (control). The reaction mixture was then diluted by the addition of 900 Wl of bu¡er B (10 mM Tris-HCl pH 8.5 containing only the anti-proteases and 10 Wg bovine serum albumin). After standing for 5 min at room temperature, the samples were centrifuged (100 000Ug, 30 min), and membrane pellets were subjected to the direct immunoblotting assay as described above. Assays were performed in duplicate.
Ras degradation
The rate of Ras degradation was determined by pulse-chase experiments [24] . Cells stably expressing K-Ras 4B(12V) or K-Ras 4B(12V) SVIM were plated at a density of 5U10 6 cells/10-cm dish in DMEM, 10% CS. One day after plating, the cells were starved of serum and methionine and pulsed with 200 WCi/ml 35 S-cysteine/methionine (1000 Ci/mmol, DuPont NEN) for 6 h. The cells were then chased by removal of the medium and addition of fresh medium (containing methionine) and 25 WM FTS or 0.1% DMSO (control). At zero time or at the indicated time periods, the cells were detached, washed in PBS and homogenized in 500 Wl of homogenization bu¡er, and the total amount of protein was determined. Following the addition of 50 Wl of U10 solubilization bu¡er containing 1% SDS, the samples were frozen for 1 h at 370³C and then thawed. Insoluble material was removed by centrifugation at 10 000Ug for 10 min. The supernatant was incubated with 2 Wg of naive rat IgG and 40 Wl of 10% protein G agarose in a total volume of 500 Wl of solubilization bu¡er containing 1% SDS. The precleared samples were incubated for 12 h with 2 Wg of Y13-259 anti-Ras antibodies coupled to agarose beads. The beads were then precipitated, washed four times with 1 ml of solubilization bu¡er containing 1% SDS and twice with 1 ml of 20 mM Tris-HCl pH 7.6, and resuspended in 25 Wl of SDS sample bu¡er. Proteins were separated by 12.5% SDS-PAGE (mini-gel), stained, destained and dried. The dried gels were exposed to X-ray ¢lm for 3^5 days and bands were analyzed as described above.
Determination of ERK activity
K-Ras 4B(12V) or K-Ras 4B(12V) CVYL cells were plated at a density of 1U10 6 cells/10 cm dish in DMEM, 10% CS. One day after plating, FTS (55 0 WM) or 0.1% DMSO (control) was added to the cells in the medium for 18 h. ERK activity was then assayed in the cell lysates. To each dish was added 1 ml of ERK lysis bu¡er (50 mM L-glycerophosphate, 1.5 mM EGTA, 2 mM sodium orthovanadate, 1 mM dithiothreitol, 2 Wg/ml leupeptin, 2 Wg/ml aprotinin, 1 mM benzamidine and 1% NP-40), and the dishes were kept on ice for 10 min. The cell lysates were collected into Eppendorf tubes, vortexed and centrifuged at 10 000Ug for 10 min at 4³C. The supernatants were collected. Samples of 500 Wg protein were then incubated for 2 h at 4³C with 5 Wl of anti-ERK-2 Ab (Santa Cruz) and 30 Wl of protein A-Sepharose beads (diluted 1:1 in ERK lysis bu¡er). The supernatant was discarded and the beads were washed three times with ERK lysis bu¡er, followed by two washes with kinase bu¡er (30 mM Tris-HCl pH 8.0, 20 mM MnCl 2 , 2 mM MgCl 2 ). Following the addition to each sample of 30 Wl of complete kinase bu¡er (containing the above kinase bu¡er and 15 Wg MBP, 10 WM ATP and 5 WCi Q 32 P-ATP (3000 Ci/mmol), samples were incubated for 30 min at 37³C. The reaction was stopped by the addition of 6 Wl of 6ULaemmli sample bu¡er and heating for 5 min at 95³C. Following a short spin, the supernatant was collected and the proteins were separated by SDS-PAGE (15% acrylamide) on mini-gels. Phos-phorylated MBP was visualized by autoradiography of the dried gels on X-ray ¢lms and quanti¢ed by densitometric analysis, as detailed above.
Results
Dislodgment and accelerated degradation of K-Ras 4B(12V)
H-and N-Ras proteins, unlike K-Ras 4B, which is farnesylated, are both farnesylated and palmitoylated [10^16]. We showed previously that FTS, whose structure resembles the farnesylcysteine of Ras, can interfere with H-Ras^membrane interactions [23, 24] . If this interference is related primarily to the farnesyl anchoring moiety of Ras, than FTS can be expected to interfere with K-Ras 4B-membrane interactions as well. To examine this possibility, we used NIH3T3 cells stably expressing the activated Ras mutant K-Ras 4B(12V). Ras proteins in the cells were determined by Western immunoblotting/ECL assays with Pan Ras Ab [24] .
In agreement with earlier studies [14] , the cells overexpressed the K-Ras 4B(12V) protein, migrated more slowly than the endogenous p21 Ras proteins 6 cells/10-cm dish and grown in 10% CS/DMEM. After 24 h, either the carrier (0.1% DMSO) or FTS (25 WM) was added. Cells were homogenized at the times indicated and Ras proteins were determined in the particulate fraction (P 100 ) and in the cytosolic fraction (S 100 ) by immunoblotting/ECL assays as described in A and in Section 2. The ¢gure shows immunoblots of a typical experiment, where 15 Wg protein of P 100 fractions and 30 Wg protein of S 100 fractions were loaded onto the gels. Densitometric analysis of the results using the TINA program, and of two additional experiments yielding similar results, indicated that FTS induced a decrease of 30 þ 12% (n = 3) and 60 þ 8% (n = 3) in the amounts of K-Ras 4B(12V) after 4 and 24 h, respectively. The total amount of K-Ras 4B(12V) in the S 100 fractions was small ( 6 10% of the amount in fraction P 100 ) even in FTS-treated cells, although relative to control there was a signi¢cant increase of 5 þ 2.5 fold (n = 3) in the amount of K-Ras 4B(12V) in S 100 after 2 h of FTS treatment. (C) FTS does not a¡ect the total membrane protein. Cells were treated for 24 h with 25 WM FTS or with 0.1% DMSO as described in B. Total protein in the particulate fraction (P 100 ) and in cytosolic fraction (S 100 ) was determined by Coomassie blue staining. The ¢gure shows gel of a typical experiment, were 7.5 Wg protein of P 100 fraction and 15 Wg protein of S 100 fraction were loaded onto the gel.
or the H-Ras protein in Rat-1 (EJ) cells due to its extra leader sequence. Experiments using a cell-free system to assay the dislodgment of Ras [24] showed that FTS (25 WM) induced a 70 þ 8% reduction in the amount of membrane-bound K-Ras (12V) (Fig. 1A) .
This e¡ect was similar to that observed under the same conditions with H-Ras ( [24] , see also Fig.  1A ). It should be noted that FTS did not induce any reduction in the amount of N-myristoylated (unfarnesylated) Ras under the same cell-free assay conditions (Fig. 1A) .
The e¡ects of FTS on K-Ras 4B(12V) were further examined in intact cells exposed to 25 WM FTS for 2, 4, and 24 h. As shown in Fig. 1B , this treatment caused a time-dependent decrease in membranebound K-Ras 4B(12V) (100 000Ug pellet, P 100 ), while it did not a¡ect the total membrane protein Fig. 3 . FTS does not a¡ect the rate of degradation of unprocessed K-Ras 4B(V12) SVIM. K-Ras 4B(12V) SVIM/NIH3T3 cells were subjected to 35 S-cysteine pulse-chase experiments under the conditions described in Fig. 2 . Results of a typical experiment (upper panel) and densitometric analysis of data obtained in two experiments are presented as the ratio of values obtained at the indicated times to values obtained at zero time.
Fig. 2. FTS facilitates degradation of K-Ras 4B(12V). K-Ras 4B(12V)/NIH3T3 cells (5U10
6 cells/10 cm dish) were pulsed with 35 S-cysteine/methionine in serum-free and cysteine/methionine-free medium for 6 h and then chased in serum-free medium, in the absence or in the presence of 25 WM FTS, for 0 12 h. Ras proteins were immunoprecipitated from total cell homogenates as described in Section 2. The immunoprecipitated proteins were separated by SDS-PAGE (12.5%), and gels were exposed to X-ray ¢lm for 48 h. The ¢gure shows the results of a typical experiment (upper panel), and densitometric analysis of data from four separate experiments presented as the ratios of values obtained at the indicated times to values obtained at zero time (mean þ S.D.). dislodgment (Fig. 1C) . The decrease of membrane bound K-Ras 4B(12V) was signi¢cant (30 þ 12%) after 4 h of treatment and was more pronounced (60 þ 8%) after 24 h. K-Ras 4B(12V) did not accumulate in the cytosol following FTS treatment (Fig.  1B) , though a signi¢cant transient increase in cytosolic K-Ras 4B(12V) was observed after treatment with FTS for 2 h. These results suggested that FTS induces dislodgment of K-Ras 4B from the cell membrane and that the dislodged protein becomes susceptible to proteolytic degradation. To test the latter possibility, we performed pulse-chase experiments. The cells were pulsed with 35 S-cysteine/methionine for 6 h and then chased in the presence or in the absence of 25 WM FTS. Ras proteins were then immunoprecipitated from the cell lysates, separated by SDS-PAGE and determined by autoradiography. The half-life of 35 S-labeled-K-Ras 4B(12V) was found to be 10^12 h in the control cells and 3^4 h in the FTS-treated cells (Fig. 2 ), indicating that FTS had increased the rate of K-Ras 4B(12V) degradation. To examine whether the e¡ects of FTS were speci¢c to the mature farnesylated K-Ras 4B(12V) protein, we performed a similar set of pulse-chase experiments with cells expressing K-Ras 4B(12V) SVIM. This Ras isoform, with its C 185 CS mutation, is not farnesylated [31] . As shown in Fig. 3 , the 35 Slabeled K-Ras 4B(12V) SVIM appeared to be relatively stable and did not undergo degradation for at least 12 h, by which time the normally processed 35 Slabeled K-Ras 4B(12V) had already decayed to about 50% of its starting level (Fig. 2) . FTS did not increase the rate of degradation of the unprocessed K-Ras 4B(12V) SVIM isoform (Fig. 3) .
FTS induces a decrease in the total amount of methylated and unmethylated K-Ras 4B(12V) isoforms and inhibits MAPK
The above ¢ndings showed that FTS can dislodge K-Ras 4B(12V) from the cell membrane in a cell-free system and in intact cells, rendering the processedb ut not the unprocessed^Ras protein susceptible to proteolytic degradation in the cells. These results suggested that FTS would induce a decrease in the total amount of cellular K-Ras 4B(12V) by facilitating its degradation. When K-Ras 4B(12V)/NIH3T3 cells were incubated for 24 h with 5^50 WM FTS, a dose-dependent decrease in the total amount of cellular K-Ras 4B(12V) was indeed observed (Fig. 4A) . It is important to note, however, that while FTS does not inhibit Ras farnesylation [23] , it can inhibit Ras methylation in vitro [21, 22] and^at relatively high concentrations ( s 50 WM)^also in intact cells [23] . To examine whether the FTS-induced decrease in KRas 4B(12V) (Fig. 4A) is associated with inhibition of Ras methylation, we used cells stably expressing K-Ras 4B(12V) CVYM. This K-Ras 4B mutant undergoes farnesylation, but because of its I 187 CY mutation there is no further processing [14] . The K-Ras 4B(12V) CVYM mutant has a slower gel migration due to its extra leader sequence, as in the K-Ras 4B(12V) mutant, and because its VYM is not removed [14] . NIH3T3 cells stably expressing K-Ras 4B(12V) CVYM were exposed to di¡erent concentrations of FTS (5^50 WM) for 24 h and the total amount of K-Ras 4B(12V) CVYM was then determined by Western immunoblotting/ECL assays with Pan Ras Ab. As shown in Fig. 4B , FTS caused a dose-dependent decrease in the total amount of K-Ras 4B(12V) CVYM. These results suggested that the e¡ects of FTS on K-Ras 4B(12V) are independent of the proteolytic removal of its VIM tripeptide and of carboxyl methylation.
The experiments described above showed that FTS can induce a signi¢cant (40^60%) reduction in the amounts of K-Ras 4B(12V) and K-Ras 4B(12V) CVYM. To ¢nd out whether the reduced amount of Ras in cells expressing these Ras mutants is manifested in Ras-dependent signaling, we next examined the e¡ects of FTS on the MAPK ERK, which is required for cell growth and transformation [33, 34] . Following treatment of the cells for 15 h with 5^50 WM FTS, ERK1 and 2 were immunoprecipitated from the cell lysates with anti-ERK Ab. ERK activity was determined with MBP as a substrate and ERK protein was determined by immunoblotting assays with anti-ERK Ab [35] . Results of a typical experiment show that FTS caused a decrease in ERK activity in K-Ras 4B(12V)/NIH3T3 cells without an e¡ect on the total amount of ERK protein (Fig. 5) . Similar results were obtained with K-Ras 4B(12V) CVYM/NIH3T3 cells. As shown in Fig. 6 , FTS caused a dose-dependent decrease in ERK activity of both K-Ras 4B(12V)/NIH3T3 cells (Fig. 6A) and of K-Ras 4B(12V) CVYM/NIH3T3 cells (Fig.  6B ).
S-Prenyl analogs speci¢cally inhibit growth of cells transformed by K-Ras 4B(12V) isoforms
The above ¢ndings that FTS can induce a decrease in K-Ras 4B(12V) and inhibit MAPK in cells ex- 6 cells/10-cm dish and grown for 15 h in DMEM/10% CS in the absence or in the presence of the indicated concentrations of FTS. The cells were lysed and ERK protein in samples of the cell lysate was determined by immunoblotting with anti-ERK Ab. ERK1 and 2 were immunoprecipitated from the cell lysates and ERK activity was determined with MBP as a substrate, as described in Section 2. The ¢gure shows phosphorylated MBP bands detected by autoradiography (A), and ERK protein bands detected with anti-ERK Ab (B).
pressing K-Ras 4B isoforms suggested that these effects might also be manifested in the inhibition of cell growth. This possibility was examined in cells grown in DMEM/10% CS in the absence and in the presence of FTS or its analogs. In agreement with previous studies [14] , both the K-Ras 4B(12V)/NIH3T3 cells and the K-Ras 4B(12V) CVYM/NIH3T3 presented transformed phenotypes forming multilayer clumps of highly refractile spindle-like cells, indicative of malignant transformation (see, for example, control cells in Fig. 7) . When the transformed cells were grown for 5 days in the presence of FTS (5^25 WM), a signi¢cant reduction in the number of cells was evident (Fig. 7) . At the concentration range of 5^25 WM FTS did not exert cytotoxic e¡ects, as determined separately by Trypan blue exclusion staining (not shown). A low degree of cytotoxicity (V10%) was observed at 50 WM FTS. Quantitative estimations of inhibition of cell growth by FTS were obtained by direct counting. Results of typical experiments (Fig. 8A) show that FTS inhibited, in a dose-dependent manner, growth of both the K-Ras 4B(12V)/NIH3T3 cells and the K-Ras 4B(12V) CVYM/NIH3T3 cells. Both cell lines appeared to display similar sensitivity to FTS, where 40^60% inhibition of cell growth was apparent at 25^50 WM FTS (Fig. 8A ). In agreement with previous results [23] , FTS had no e¡ect on the growth of the parental NIH3T3 cells at concentrations of 5^25 WM and only a small inhibitory e¡ect (10^20%) at 50 WM (Fig.  8A) . Similarly, FTS did not a¡ect the growth of NIH3T3 cells stably expressing the unprocessed K-Ras 4B(12V) SVIM mutant (Fig. 8B) .
Next we examined the speci¢city of the inhibitory e¡ect of FTS. In these experiments, cells that express the normally processed K-Ras 4B(12V) isoform were exposed to S-prenyl analogs other than FTS. As shown in Fig. 8C , N-acetyl-S-farnesylcysteine (AFC), previously shown to lack growth-inhibitory e¡ects in H-Ras transformed cells [25] , also did not inhibit growth of the K-Ras 4B(12V)-transformed cells. Similarly, the C 10 geranyl analog GTS did not inhibit growth of these cells, but the C 20 geranylgeranyl derivative GGTS and the 5-£uoro analog of FTS were as potent as FTS (Fig. 8C) . As shown in Fig. 9A , GGTS (50 WM) also induced a signi¢cant decrease (40%) in membrane-associated K-Ras 4B(12V). These structure^function relationships, which resemble those observed in H-Ras-transformed Rat-1 cells [25] , suggest that distinctive structural elements are required in S-prenyl derivatives for the growth inhibition of Ras-transformed cells.
Taken together, these results demonstrate a positive correlation between the FTS-induced dislodgment of farnesylated K-Ras 4B(12V) and growth inhibition of cells transformed by activated K-Ras 4B. In this connection, it is important to note that K-Ras 4B can undergo S-prenylation by the enzyme geranylgeranyltransferase I, especially under conditions where the enzyme farnesyl transferase is blocked [26^29]. Moreover, activated geranylgeranylated Ras proteins exhibit transforming activity, most probably because of their ability to associate with the cell membrane and activate Ras-dependent signaling pathways that lead to cell transformation [13, 15, 30] . It was therefore of interest to examine whether FTS can a¡ect geranylgeranylated K-Ras 4B and inhibit growth of cells transformed by this Ras isoform. This was tested in cells that stably express the mutant K-Ras 4B(12V) CVIL, which serves as a substrate for geranylgeranyltransferase I, but not for farnesyltransferase [14, 15] . As shown in Fig.  9B , FTS induced a signi¢cant reduction (37% at 50 WM) in the amount of membrane K-Ras 4B(12V) CVIL. FTS also inhibited, in a dose-dependent manner, the growth of the K-Ras 4B(12V) CVIL/ NIH3T3 cells (Fig. 8B) , suggesting that FTS can a¡ect K-Ras 4B functions whether it is farnesylated or geranylgeranylated.
Discussion
As with all Ras proteins, membrane anchorage of K-Ras 4B is promoted by its carboxy-terminal Sfarnesylcysteine carboxy methyl ester, but unlike HRas, N-Ras and K-Ras 4A, in which membrane anchorage also requires palmitoylation, K-Ras 4B requires its sequence of six lysine residues adjacent to the farnesylated cysteine [3,10^15] . In earlier studies, we found that the constitutively active form of the more heavily lipidated H-Ras(12V) protein can be dislodged from the cell membrane by FTS [23, 24] . We postulated that the e¡ect of FTS could represent interference of the drug in the interaction between the S-farnesyl moiety of H-Ras and a speci¢c membrane-anchorage domain. This possibility was supported by experiments demonstrating that interference with H-Ras(12V) functions requires the presence of distinctive structural elements in S-prenyl analogs of FTS [21, 25] , as well as by experiments demonstrating a lack of FTS e¡ects on the genetically engineered N-myristoylated (unfarnesylated) Ras protein [24] . The hypothesis predicted that FTS, which resembles the structure of the S-farnesylcysteine common to all Ras proteins, would also interfere with membrane association of K-Ras 4B, which is not lipidated by lipids other than a farnesyl group. The present work demonstrates that this is indeed the case. It shows that FTS can dislodge K-Ras 4B(12V) from putative anchorage sites in the membrane (Fig. 1) and accelerate its rate of degradation (Fig. 2) . These e¡ects were accompanied by a decrease in the total amount of K-Ras 4B(12V) (Fig. 4) and inhibition of ERK activity in the K-Ras 4B(12V)-transformed cells (Figs. 5 and 6 ) and inhibition of cell growth (Figs. 7 and 8) .
The FTS-induced decrease in K-Ras 4B(12V) and in ERK activity occurred at the concentration range (5^50 WM) at which FTS inhibited growth of the K-Ras 4B(12V)-transformed cells (Figs. 7 and 8) . A similar correlation was described in cells transformed by H-Ras(12V) [21, 25, 35] , a Ras isoform that is both farnesylated and palmitoylated [3,10^15] . It thus appears that growth inhibition of Ras-transformed cells by FTS is primarily associated with its ability to disrupt the interactions between the S-farnesyl moiety of Ras proteins and the cell membrane. It is certainly possible that FTS may inhibit the growth of some Ras-transformed cells because their proliferation is driven by a number of prenylated proteins, not because it is being driven by Ras speci¢cally. Indeed, in some cases, this may be true, and we do not mean to suggest here that it cannot be so. However, the likely existence of other prenylated target proteins does not alter the importance of the ¢nding that, where the growth of transformed cells is driven by activated K-Ras, as it is in the NIH cell lines studied here, FTS (but not FTI) can inhibit their growth. It is also important to re-iterate that FTS does not inhibit the growth of every type of a transformed cell line. We showed in a previous study that SV40 T-antigen transformed cells were not inhibited, whereas ErbB2-transformed cells were [23] . It is well established that T-antigen transformation is not dependent upon Ras (although they can cooperate), whereas ErbB2 transformation, by contrast, is dependent upon Ras function. These data provide additional support for the idea that inhibition of Ras function has a greater in£uence in determining sensitivity to FTS growth inhibition than does transformation in general. In addition to these results, we have also shown evidence that the growth of cells transformed by a myristoylated (non-prenylated) form of Ras is not a¡ected by FTS treatment [24] . These cells are every bit as rapidly growing as cells transformed by farnesylated Ras proteins and thus represent an excellent control for the growth inhibitory action of FTS due to inhibition of prenylated Ras.
Support for the notion that the mechanism of action of FTS is associated primarily with its e¡ects on membrane-bound K-Ras 4B(12V) or membranebound H-Ras(12V) [24] comes from additional experiments in the present study. Previous studies have shown that farnesylation of K-Ras 4B(12V) is su¤cient for its membrane anchorage and transform-ing activity. This is because the K-Ras 4B(12V) CVYM mutant presents activities similar to those of K-Ras 4B(12V) mutant, yet its VYM tripeptide is not removed by the CAAX protease and thus K-Ras 4B(12V) CVYM is not carboxyl methylated [14] . Here we show that FTS induces a decrease in the amount of K-Ras 4B(12V) CVYM (Fig. 4) and inhibits the growth of cells transformed by this Ras mutant (Fig. 8) . Clearly, then, growth inhibition by FTS cannot be ascribed to inhibition of the CAAX protease or to inhibition of the methyltransferase. This conclusion is consistent with earlier studies demonstrating that FTS does not inhibit H-Ras methylation in intact cells at the concentration range at which it inhibits cell growth [23] . It is also important to note that FTS does not inhibit farnesylation of H-Ras by the enzyme farnesyltransferase [23] . Although we did not test this directly with mutants of K-Ras 4B, it is very unlikely that FTS inhibited their farnesylation. Such an e¡ect would have caused accumulation of unprocessed K-Ras 4B in the cytosol [31] , and this was not observed in our experiments (Fig. 1) . As a ¢nal point in connection with post-translational modi¢cations in Ras proteins, it is worth reiterating that the observed FTS-induced dislodgment ( Fig. 1 ) and accelerated degradation (Fig.  2 ) of K-Ras 4B(12V) clearly demonstrate that the e¡ect of the drug is independent of Ras palmitoylation. Together with previous ¢ndings on H-Ras (12V), the present data indicate that FTS a¡ects the mature membrane-bound forms of Ras proteins and not their processing. This emphasizes the substantial di¡erence between the mechanism of action of FTS and of farnesyltransferase or geranylgeranyltransferase inhibitors that inhibit Ras processing [364 1]. The precise mechanism through which FTS and its active analogs a¡ect Ras-membrane interactions ( Figs. 1 and 2 ) and subsequently inhibit the growth of H-Ras-transformed [21, 23, 24] and K-Ras-transformed cells (Figs. 7 and 8) is not yet known. We do know, however, that this mechanism involves a rather speci¢c disruption of Ras-membrane anchorage. First, growth inhibition of cells that express activated Ras isoforms by prenyl analogs clearly depends on the structure of such analogs. For example, farnesol, farnesoic acid, S-farnesylthiopropionic acid, AFC, and the C 10 S-prenyl derivative GTS do not inhibit the growth of H-Ras-transformed cells, whereas FTS, its 5-£uoro and 5-chloro derivatives, and the C 20 derivative GGTS are active inhibitors [25] . Similar structure^activity relationships were observed here in K-Ras 4B(12V)-transformed cells (Fig. 8 ) and in Panc-1 cells that express activated K-Ras(12V) [42] . Second, the genetically engineered N-myristoylated (unfarnesylated) Ras mutant that is inserted non-speci¢cally into the cell membrane is not a¡ected by FTS in vivo [24] or in vitro (Fig. 1 ). This suggests interference by FTS with the interactions between the S-farnesylcysteine of Ras and speci¢c membrane-anchorage sites. Both wild-type Ras and activated Ras proteins were found to be localized in speci¢c membrane domains such as caveolae, or related domains enriched in glycosphingolipids and cholesterol [17^20] . FTS may exert its e¡ect by interfering with the interactions between Ras and a Ras-binding protein [43] or between Ras and speci¢c lipids or proteins present in caveolae or related membrane domains. Third, we recently observed that FTS can alter the lateral mobility of the green-£uorescent K-Ras 4B(12V) fusion protein (GFP-K-Ras) with no e¡ect on the bulk of the membrane lipids in the membranes of live cells [44] . These observations, together with the knowledge that Ras proteins are localized in membrane microdomains [17^20], also suggest that FTS targets H-Ras [24] and K-Ras (Figs. 1 and 2 ) associated with lipids and/or proteins of glycosphingolipid/cholesterol-enriched domains. In this connection it is interesting to note that FTS inhibited the growth of cells transformed by the geranylgeranylated K-Ras 4B(12V) CVIL mutant (Fig. 8B) . These data, along with the ability of GGTS to mimic the actions of FTS (Fig.  8C) , suggest that Ras-recognition domains in the cell membrane can tolerate an extended (C 20 ) S-prenyl moiety.
Since most GLQ subunits of the heterotrimeric Gproteins are geranylgeranylated, the previously observed lack of FTS e¡ect on these membrane-associated proteins [24] could have led to the expectation that FTS will not a¡ect membrane-bound geranylgeranylated-Ras. This, however, was not the case (Fig. 9) . A possible explanation for these observations is that K-Ras 4B and GLQ localize to distinct membrane domains or anchor di¡erently within a same microdomain. The geranylgeranylated K-Ras 4B(12V) would then associate, like farnesylated KRas 4B(12V), with domains that preferentially associate Ras and not GLQ. Recent experiments demonstrated distinct membrane domains in mouse melanoma B16 cells where Rho A and c-Src were found to be localized in GM3-enriched fractions, whereas Ras and caveolin were found to be localized in glucosylceramide/cholesterol-enriched domains [45] . These experiments and the recent observations that even K-Ras and H-Ras appear to associate with different membrane domains [46] make the above explanation possible, though other possibilities cannot be ruled out.
It is worth noting that the e¡ects of S-prenyl analogs, such as FTS on Ras are manifested not only in a decrease in the amount of membrane-bound Ras. We know of at least two additional FTS-related effects on Ras. The ¢rst was detected in experiments with GFP-K-Ras, where we found that following FTS treatment the residual Ras in the cell membrane presents impaired membrane interactions [44] . More speci¢cally, we found that FTS has a biphasic e¡ect on GFP-K-Ras lateral mobility. At the initial phase, the lateral di¡usion rate of GFP-K-Ras was elevated, suggesting that it is released from some constraints on its lateral mobility. This was followed by dislodgment of the protein into the cytoplasm, and reduction in the di¡usion rate of GFP-K-Ras that remained associated with the plasma membrane. This is important because in all types of cells tested so far, we ¢nd that FTS reduces the amount of Ras only by 50^80% [23, 24] . A signi¢cant amount of activated H-Ras [24] or K-Ras (Figs. 1 and 3 ) therefore remains in the cell membrane. The above observation suggests that in addition to the FTS-induced reduction in the amounts of active Ras, FTS disrupts the interaction of residual Ras with the membrane. An additional FTS-related e¡ect is the drug-facilitated degradation of H-Ras(12V) [24] and of K-Ras 4B(12V) (Fig. 3) . This e¡ect certainly explains why the total amount of Ras is reduced in FTS-treated cells. It also suggests that dislodgment of Ras from its putative anchorage sites by FTS renders the protein susceptible to proteolytic degradation. We do not know, however, whether or not degradation of Ras is accomplished by unique enzymes. The data demonstrating that FTS-accelerated degradation of the fully processed K-Ras 4B(12V) (Fig. 2) , but not of the unprocessed K-Ras 4B(12V) SVIM mutant (Fig. 3) , along with the latter's very slow degradation rate, suggest that speci¢c degradation of Ras requires its farnesyl moiety. The precedence of the CAAX protease, which acts speci¢cally on farnesylated Ras proteins [47] , is an example of such a requirement in a proteolytic enzyme.
The present study provides mechanistic explanations for the action of FTS on Ras and points to the signi¢cance of putative Ras-anchorage sites within membrane domains. It may also have important therapeutic implications. K-Ras 4B is the major alternative splice product of the mammalian K-Ras gene [8] . This Ras isoform and the N-Ras isoform are the most frequently detected Ras oncoproteins in human tumors [7, 8] . Compounds that a¡ect K-Ras and N-Ras oncoproteins may therefore be considered as potential anti-cancer drugs. FTS, with its ability to a¡ect H-Ras(12V) [23^25], K-Ras 4B(12V) (Figs. 1^3) and N-Ras (B. Jansen and Y. Kloog, unpublished observations), seems to represent such a potential anti-tumor drug. It is important to note in this connection that K-Ras 4B and N-Ras can act as substrates for the enzyme geranylgeranyltransferase I [26^29], and that they are indeed geranylgeranylated when farnesyltransferase activity is blocked by speci¢c inhibitors [28, 29] . Because constitutively active geranylgeranylated Ras proteins are active biologically, it seems that the inhibition of cell and tumor growth by farnesyltransferase inhibitors is caused by the inhibition of as yet unknown farnesylated proteins, and not by the direct blockage of K-or N-Ras functions [3] . As we have indicated in the current manuscript, the claim for the importance of inhibition of K-Ras 4B comes from two types of results. First, FTS does not inhibit the growth of Raf-transformed cells or cells transformed by T-antigen [23] . Second, in the same publication and in related studies [23] , we have demonstrated clearly that FTS does not block the growth of normal cells. Therefore, the ability of FTS to inhibit the growth of Ras-but not Raf-transformed cells argues that Ras-but not Raf-transformed or normal cell growth is indeed driven by a prenylated protein which can be inhibited by FTS. In the case of the cells tested here, the most important prenylated protein is K-Ras 4B. In other cell types (not Raf-transformed or normal cells) other prenylated proteins may be important.
The fact that FTS can target K-Ras, which is insensitive to inhibition by FTIs, suggests that FTS may target Ras (and any other prenylated proteins important for transformed cell growth) in an e¤cient manner that speaks well for its potential as an anti-cancer therapeutic agent. This possibility, and the present results demonstrating that FTS inhibits the growth of cells transformed by geranylgeranylated K-Ras 4B, also suggest that a combined treatment of FTIs and FTS might result in synergistic inhibitory e¡ects on cells transformed by K-Ras 4B or by N-Ras.
